Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCT-817
- Development stage
- Preclinical
- Lead developer
- Canary Cure
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CCT-817 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Canary Cure (also known as Canary Global) for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Developed using the company's 'Reprogram Platform' and 'Thermogenic Adipose Reprogramming' technology, CCT-817 is designed to promote the 'browning' of white adipose tissue (WAT). This process involves reprogramming energy-storing white adipocytes into energy-expending thermogenic adipocytes, thereby increasing metabolic rate and facilitating weight loss. The drug is part of a pipeline focused on thermogenic adipose reprogramming to address metabolic diseases through targeted gene silencing.
- Other names
- CCT 817CCT817CCT-817
Beyond the preview
Go deeper on CCT-817.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCT-817.